Patients’ rights advocates are applauding President Donald Trump’s latest effort to expand prescription drug price transparency, arguing that the move represents an important step toward broader healthcare transparency and accountability.
Among those praising the initiative is Cynthia Fisher, founder and chairman of PatientsRightsAdvocate.org (PRA), who said the administration’s actions could help consumers better understand healthcare costs and make more informed decisions.
“We applaud President Trump, Secretaries Kennedy and Oz, Mark Cuban, and all those involved for expanding consumer choice in prescription drug pricing, which is a critical first step toward true price transparency in healthcare,” Fisher told The Center Square.
Fisher noted that prescription medications account for a significant share of healthcare spending for American families and said transparency efforts should extend beyond pharmaceuticals.
“Prescription medications account for nearly 15% of healthcare spending for American families, which is why President Trump’s broader healthcare agenda also targets hospital and insurance pricing,” she said.
According to Fisher, greater transparency throughout the healthcare system could encourage competition while helping consumers and employers identify and avoid unnecessary costs.
“Full transparency across prescription drugs, hospital services, and insurance pricing will promote competition, empower consumers and employers, and help prevent the overcharges that drive up healthcare costs for working families and businesses alike,” she said.
Fisher also pointed to private-sector efforts such as Mark Cuban’s Cost Plus Drugs as examples of how transparent pricing models can reduce costs and improve access to medications.
“Transparent models like Mark Cuban’s Cost Plus Drugs have demonstrated how openness and competition can directly lower costs and expand access,” she said.
She added that Trump’s transparency initiatives have created an opportunity to reshape the healthcare marketplace and improve accountability.
Former Domestic Policy Council Director Andrew Bremberg echoed those sentiments, arguing that healthcare consumers increasingly want greater visibility into how prices are determined.
“Americans are tired of hidden prices, surprise bills, and unexplained costs,” Bremberg said.
“They want accountability.”
Bremberg emphasized that healthcare price transparency is not primarily a partisan issue but one that affects patients, employers, and taxpayers alike.
“And unlike many healthcare debates, this is not fundamentally about ideology,” he said. “It is about whether patients, employers, and taxpayers deserve to know where their money is going.”
He added that stronger enforcement of transparency requirements could provide immediate benefits for consumers seeking affordable care.
“Maximum price transparency enforcement is the fastest way to empower Americans and make healthcare affordable again, and the Trump Administration can get it done,” Bremberg said.
The comments follow Trump’s announcement that TrumpRx, a government-backed prescription drug discount website, will significantly expand its offerings. According to the president, the platform will grow to roughly seven times its current size by adding more than 600 generic prescription medications.
Trump promoted the expansion during a healthcare affordability event, where he called for “unprecedented price transparency” throughout the healthcare system.
The administration has made healthcare price transparency a major policy priority this year, building on previous efforts aimed at making pricing information more accessible to consumers.
The renewed focus comes as healthcare affordability remains a top concern for many Americans. A recent Pew Research Center survey found that 73% of adults say the affordability of healthcare is a very big problem facing the country.
According to the TrumpRx website, the platform allows Americans to purchase prescription medications with cash outside of traditional insurance plans, with the goal of offering some of the lowest prescription drug prices available in the developed world.
Supporters of the initiative argue that expanding access to pricing information could help patients comparison shop, reduce costs, and bring greater accountability to a healthcare system that many Americans view as difficult to navigate.
